prmaconsulting®

PART OF FISHAWACK HEALTH

Global HTA/P&R review for CAR-Ts in rare oncological diseases

SUMMARY

The client wanted to critically review HTA decisions for chimeric antigen receptor T-cell (CAR-T) products to be able to refine their own evidence generation strategy for a pipeline CAR-T asset.

OUR APPROACH

Data extraction

A total of 47 HTA and reimbursement decisions was identified in acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and primary mediastinal large B-cell lymphoma. The final HTA and reimbursement decisions were reviewed for each, including:

- detailed information on submitted clinical and economic data
- a summary of key criticisms from review committees.

Strategic recommendations were made across 12 domains and five key themes

- The implications for the client's asset were summarized as strategic insights.
- A clear comparison of the strategies was developed and the key drivers for HTA decisions identified.
- Five key themes across all insights and recommendations were identified.
- Actionable recommendations were made to evolve the evidence generation activities planned within the asset's pipeline indications.

Global HTA/P&R review for CAR-Ts in rare oncological diseases

01 Greater relevance of ITT population

02 Requirement for comparative data

03 Value of demonstrating long-term benefit/ curative potential

04 Uncertainty about size of eligible patient population

05 Demonstrating cost-effectiveness

Access to PRMA Tracker®

- Data were collated within a digital application, including comprehensive information on the submitted clinical and economic evidence, and key criticisms from review committees.

- The PRMA Tracker® provides a global timeline overview of the payer landscape, easily customized with filters.